Current treatment approaches in CML.

Take home messages Five tyrosine kinase inhibitors are available, the treatment strategy is still challenging. Baseline risk, comorbidities, and patient and physician expectations play a pivotal role. Treatment-free remission is a new opportunity

FDG-PET in the management of germ cell tumor

n/

Transient inverse energy cascade in free surface turbulence

We study the statistics of free-surface turbulence at large Reynolds numbers produced by direct numerical simulations in a fluid layer at different thickness with fixed characteristic forcing scale. We observe the production of a transient inverse cascade, with a duration which depends on the thickness of the layer, followed by a transition to three-dimensional turbulence initially produced close to the bottom, no-slip boundary. By switching off the forcing, we study the decaying turbulent regime and we find that it cannot be described by an exponential law. Our results show that boundary conditions play a fundamental role in the nature of turbulence produced in thin layers and give limits on the conditions to produce a two-dimensional phenomenology.Comment: 9 pages, 8 figure

On-Off Pumping for Drag Reduction in a Turbulent Channel Flow

We show that the energy required by a turbulent flow to displace a given amount of fluid through a straight duct in a given time interval can be reduced by modulating in time the pumping power. The control strategy is hybrid: it is passive, as it requires neither a control system nor control energy, but it manipulates how pumping energy is delivered to the system (as in active techniques) to increase the pumping efficiency. Our control employs a temporally periodic pumping pattern, where a short and intense acceleration (in which the pumping system is on) followed by a longer deceleration (in which the pumping system is off) makes the flow alternately visit a quasi-laminar and a turbulent state. The computational study is for a plane channel flow, and employs direct numerical simulations, which present specific computational challenges, for example the highly varying instantaneous value of the Reynolds number, and the importance of discretisation effects. Particular care is devoted to a meaningful definition of drag reduction in the present context. The ability of the forcing to yield significant savings is demonstrated. Since only a small portion of the parameter space is investigated, the best performance of the control technique remains to be assessed

Hematopoetic stem cell transplantation for solid tumors in Europe

Background: Hematopoetic stem cell transplants (HSCT) are discussed as treatment options for patients with solid tumors. Transplant numbers have changed substantially over the last decade, few controlled studies are available and different opinions prevail. Objective information on current practice is needed. Patients and methods: Data from 27 902 HSCT for solid tumors (2% allogeneic, 98% autologous), collected by the European Group for Blood and Marrow Transplantation (EBMT) activity survey from 1991 to 2002 were used to assess trends, transplant rates and coefficient of variation of transplant rates in Europe. Results: Transplant numbers increased from 536 in 1991 to 4154 in 1997 and decreased to 1913 in 2002. Indications were neuroblastoma (2504 HSCT; 9%), glioma (662 HSCT; 2%), soft tissue sarcoma (1253 HSCT; 4%), germ cell cancer (3291 HSCT; 12%), breast cancer (13 524 HSCT; 48%), Ewing's sarcoma (1896 HSCT; 7%), lung cancer (387 HSCT; 1%), ovarian cancer (845 HSCT; 3%) and other solid tumors (3540 HSCT; 14%). Allogeneic cells were used in <20 cases up to 1997; since then allogeneic HSCT increased to 159 in 2002, mainly for renal cell carcinoma. Low coefficients of variation in transplant rates (<60%) are observed for Ewing's sarcoma (<56.5%), suggesting consensus for this indication. Conclusions: These data give an overview on current practice of HSCT for solid tumors in Europe. They provide objective information for health-care providers and patient counsellin

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients. The most frequent clinically relevant mechanisms that change imatinib sensitivity in BCR-ABL-transformed cells are mutations within the Abl kinase domain, affecting several of its properties. Crystal structure analysis of the Abl-imatinib complex has proven helpful in identifying potential critical residues that hinder interactions of imatinib with mutated Abl. This has led to the development of a second generation of targeted therapies such as nilotinib and dasatinib, already in phase II clinical trials or SKI-606 and MK-0457 in phase I trials. In this review, we discuss the activity of nilotinib, developed by Novartis using a rational drug design strategy in which imatinib served as the lead compound. Preliminary studies demonstrated that nilotinib has more efficacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profile and clinical efficacy in all phases of CML

Therapeutic potential of endothelial colony‐forming cells in ischemic disease: Strategies to improve their regenerative efficacy

Cardiovascular disease (CVD) comprises a range of major clinical cardiac and circulatory diseases, which produce immense health and economic burdens worldwide. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. In turn, circulating endothelial colony‐forming cells (ECFCs) represent truly endothelial precursors, which display high clonogenic potential and have the documented ability to originate de novo blood vessels in vivo. Therefore, ECFCs are regarded as the most promising cellular candidate to promote therapeutic angiogenesis in patients suffering from CVD. The current briefly summarizes the available information about the origin and characterization of ECFCs and then widely illustrates the preclinical studies that assessed their regenerative efficacy in a variety of ischemic disorders, including acute myocardial infarction, peripheral artery disease, ischemic brain disease, and retinopathy. Then, we describe the most common pharmacological, genetic, and epigenetic strategies employed to enhance the vasoreparative potential of autologous ECFCs by manipulating crucial pro‐angiogenic signaling pathways, e.g., extracellular‐signal regulated kinase/Akt, phosphoinositide 3‐kinase, and Ca2+ signaling. We conclude by discussing the possibility of targeting circulating ECFCs to rescue their dysfunctional phenotype and promote neovascularization in the presence of CVD

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

n/